This ASH 2025 conference video features expert perspectives on newly published ASH guidelines for the treatment of newly diagnosed older adults with acute myeloid leukemia (AML). Discussion focuses on individualized treatment selection, molecular risk–informed decision-making, assessment of transplant eligibility, and the role of supportive and end-of-life care.
The video also reviews real-world evidence evaluating anti-inflammatory approaches for the management of immune effector cell–associated neurotoxicity syndrome (ICANS) following CAR T-cell therapy, highlighting evolving strategies to address this challenging toxicity in clinical practice.
Share your thoughts
